Welcome to our dedicated page for Supernus Pharma news (Ticker: SUPN), a resource for investors and traders seeking the latest updates and insights on Supernus Pharma stock.
Supernus Pharmaceuticals develops and commercializes treatments for central nervous system diseases. Company news centers on its neuroscience portfolio, including approved treatments for attention-deficit hyperactivity disorder, Parkinson's disease-related dyskinesia and hypomobility, postpartum depression, epilepsy, migraine, cervical dystonia, and chronic sialorrhea.
Recurring updates cover product revenue trends for Qelbree, GOCOVRI, ZURZUVAE, ONAPGO and other CNS therapies, quarterly financial results, collaboration and licensing revenue, investor conference participation, and pipeline activity for novel CNS product candidates such as SPN-820 in major depressive disorder.
Supernus Pharmaceuticals, Inc. will host a webcast on May 23, 2024, to discuss interim data from the Phase IIa study of SPN-817 for treatment-resistant seizures. Investors can access the live webcast and presentation slides on the Company's Investor Relations website. A replay will be available for 60 days.
Supernus Pharmaceuticals, Inc. reported strong financial results for the first quarter of 2024, with net sales of Qelbree® increasing by 75% to $45.1 million. Total revenues were $143.6 million, with a 12% increase in revenues excluding Trokendi XR® and Oxtellar XR® net product sales. The Company reiterates its full year 2024 financial guidance, including total revenue guidance of $580 - $620 million. Key product pipeline updates include SPN-830 for Parkinson's disease and SPN-820 for depression. The Company also announced the initiation of a Phase I study for SPN-443 for ADHD/CNS.
M8 Pharmaceuticals, an Acino company, has signed an exclusive licensing agreement with Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) to commercialize Qelbree® (Viloxazine XR) in Latin America. Qelbree® is an extended-release capsule approved to treat ADHD in the US. This partnership aims to provide innovative treatment options for patients in Latin America.
Busy Philipps partners with Supernus Pharmaceuticals to share her experience with ADHD and treatment with Qelbree, a non-stimulant medication. The partnership aims to raise awareness during Mental Health Awareness Month for the millions of adults living with ADHD in the US.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.